ReviewFrontiers in aging neuroscience2026
Multidimensional iron dysmetabolism and gut-brain axis interactions in restless legs syndrome: from peripheral deficiency to central dysregulation.
Review in Frontiers in aging neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Restless Legs Syndrome (RLS) is a sensorimotor neurological disorder characterized by an irresistible urge to move the lower limbs. Although traditional paradigms attribute its pathogenesis to peripheral iron deficiency, many clinically diagnosed patients present with normal peripheral iron indicators yet exhibit central iron homeostatic dysregulation. This discrepancy highlights a distinct decoupling between peripheral iron stores and central iron availability. The RLS-associated iron metabolic impairment is inherently a complex pathological network orchestrated by multidimensional processes, including intestinal absorption, systemic distribution, blood-brain barrier (BBB) transport, and intracellular utilization. Crucially, gut dysbiosis-induced low-grade enterogenous inflammation may activate the IL-6/hepcidin pathway, thereby sequestering systemically available iron; this mechanism represents a pivotal upstream driver of central iron insufficiency. Consequently, impaired cerebral iron utilization disrupts the physiological equilibrium of neurotransmitter systems-namely dopamine, adenosine, and glutamate-ultimately triggering the sensorimotor symptoms and sleep disturbances characteristic of RLS. Therefore, clinical management should shift away from relying solely on isolated peripheral indicators toward implementing individualized iron supplementation phenotyped by specific absorption, distribution, or transport mechanisms. Looking forward, microecological interventions utilizing prebiotics or short-chain fatty acids (SCFAs) to mitigate systemic inflammation and ameliorate the intestinal environment hold substantial promise as a synergistic therapeutic strategy for RLS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.